In a phase 1/2 study of rinatibet sesutecan (Rina-S) known as the PRO1184-001 study, another new ADC targeting FRα was tested in patients with locally advanced and/or metastatic solid tumors like ovarian tumors, NSCLC, breast and endometrial tumors, or mesothelioma. Here, FOLR1 is linked to ovarian neoplasm.